The stock is up about 1 percent today, continuing a week of very little movement, and remains just below its recent high from a few days ago. We think this is mostly ordinary movement and the whole market drifting higher, as there is no new company news today.
Our view
The business is successfully shifting toward owning its own plasma collection centers, which should help it earn more profit on every sale over time. If you already own the stock, there is nothing to do here but sit tight and wait for next week's update.
The company will share its latest earnings and a business update on Wednesday, August 12. This will be the first full look at how its new plasma collection centers in the U.S. are contributing to profit margins.
The firm set a target of $15, which is more than double the current stock price. This reflects a more optimistic view than the average analyst target of $13. It suggests confidence in the company's shift toward owning its own plasma supply and higher-margin specialty treatments.
This agreement is a direct result of Kamada's recent expansion into plasma collection. By selling its surplus specialty plasma to other firms, the company is creating a new, high-margin revenue stream that is separate from its own drug manufacturing.
The $50 million total value over three years is meaningful for a company that brought in about $180 million in total revenue last year. It validates the strategy of becoming a vertically integrated supplier rather than just a drug maker.
Study shows improved outcomes for lung transplant treatment
The study focused on patients at high risk for CMV, a common and dangerous virus for transplant recipients. Results showed that using Cytogam was linked to better clinical outcomes. This data provides a clear reason for doctors to use the treatment more often, supporting one of Kamada's key proprietary products.
Analysts have maintained a steady string of buy ratings following the company's recent $50 million sales agreement. Five of the six analysts rate the stock a buy, with an average target of $13 that suggests 80% upside.
Average target$13+80%vs $7.21 today
TodayAvg price
Low $11High $15
Strong Buy6 analysts
0Bearish
1Neutral
5Bullish
FirmRatingPrice TargetDate
William Blair
—
$15
7/21/2026
Stifel Nicolaus
—
$11
3/11/2026
H.C. Wainwright
—
$11→$13
12/9/2025
Stifel Nicolaus
—
$20
11/13/2024
Kamada earnings
The company has a history of beating expectations, though it has found it harder to clear the bar in the most recent three quarters.
Earnings history
EstimateBeatMiss
Kamada past earnings results
Expected
Actual
Surprise
EPS
$0.12
$0.07
-41.7%
Revenue
$47M
$45M
-3.2%
Key highlights
Profit and revenue outlook affirmed: Management reaffirmed their 2026 goal of reaching $200 million to $205 million in revenue and $50 million to $53 million in adjusted EBITDA, which would be a 23% increase in earnings over last year. This shows the company expects to catch up in the coming months after missing first-quarter expectations.
Revenue growth slowed by delay: Total revenue grew 3% to $45.2 million, but this was lower than it could have been because a single large order was delayed and not delivered until April. The company says demand for its rare disease products remains high, and sales for this specific order will show up in the next quarterly report.
Distribution segment expanding quickly: Revenue from the distribution business, which sells other companies' drugs in Israel and the Middle East, more than doubled to $9.0 million from $4.0 million last year. This part of the company is becoming a bigger piece of the business as it launches new biosimilars, which are lower-cost versions of brand-name biological medicines.
Profit margins feeling pressure: Gross margins, which show the percentage of sales left after production costs, fell to 42% from 47% a year ago. Management says this dip was caused by the specific mix of products and markets where they sold goods this quarter, rather than a permanent increase in costs.
Plasma center expansion continuing: The company now has three FDA-approved plasma collection centers in Texas after receiving final clearance for its San Antonio location in February 2026. These centers are important because they allow the company to collect its own raw materials for its therapies, which can lower costs and make the supply chain more reliable.
Our take: This was a soft quarter on the surface because of a shipment delay, but the business is still fundamentally healthy. We are encouraged that management kept their full-year profit targets of at least $50 million. The rapid growth in the distribution segment and the new plasma center approval keep the long-term growth story on track.
Kamada’s next earnings date
Q2 2026
AUG
12
Expectation
EPS
$0.12
Revenue
$51M
Metrics we are tracking
Metric
Expectations
Status
Revenue Growth
Sustaining annual growth between 10% and 12%
3% YoY in Q1 2026
Adjusted EBITDA
Reaching the $50 million to $53 million guidance range
$11.6 million in Q1 2026
Plasma Collection Capacity
Full commercial operation of three Texas centers by year-end
